We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Earnings Surpass Estimates in Q2, Improve Y/Y
Read MoreHide Full Article
Cigna Corp.’s (CI - Free Report) second-quarter 2020 earnings of $5.81 per share surpassed the Zacks Consensus Estimate by 15% and also grew 35% year over year.
Results reflected revenue and earnings growth owing to a strong fundamental performance and lower medical costs from deferred care following the COVID-19 pandemic.
Cigna’s revenues of $39.3 billion beat the Zacks Consensus Estimate by 4.2% and also increased 13.9% year over year mirroring solid contributions from each of the company's ongoing businesses.
The company’s medical enrollment grew by 86,000 lives from the prior-year quarter to 17.083 million customers, attributable to membership gains in the Government and International markets.
Selling, general and administrative expense ratio was 8.4, improved 60 basis points year over year on significant growth in revenues and cost-control measures.
Cigna Corporation Price, Consensus and EPS Surprise
Health Services: Adjusted revenues of $28.6 billion were up 21.5% year over year, driven by insourcing of Integrated Medical pharmacy volumes and a sturdy performance in specialty pharmacy services, partly offset by a decline in retail script volumes.
Operating income of $1.25 billion increased 7% year over year, representing customer growth, higher adjusted pharmacy scripts volumes, benefits from effective management of the supply chain and a steady performance in specialty pharmacy services, partially offset by an increase in operating expenses to support growth
Integrated Medical: Adjusted revenues of $9.23 billion were up 3% year over year, highlighting customer wins in Medicare Advantage and in the Select segment, as well as premium growth. However, this upside was partially offset by premium relief programs for clients that were carried out in response to the COVID-19 pandemic.
Operating income of $1.52 billion surged 53.83% year over year on significantly lower medical utilization in both the Commercial and Government segments compared with the historic patterns. However, this uptrend was partially offset by premium relief programs for clients and cost share waivers for customers.
International Markets: Adjusted revenues of $1.43 billion were up 3.1% year over year, reflecting consistent business growth, partially offset by an adverse foreign currency movement.
Operating earnings of $319 million soared 54.1% year over year, driven by lower claim levels amid the COVID-19 pandemic, constant business gains and operational efficiency.
Group Disability and Other Operations
Adjusted revenues of $1.33 billion inched up 1.5% year over year. Operating earnings of $132 million were down 11.4% year over year due to elevated claims in Cigna’s Life business, primarily related to the COVID-19 pandemic. However, this downside was partially mitigated by a favorable performance within the Disability business.
Capital Position
Cigna’s debt-to-capitalization ratio improved to 43.5 as of Jun 30, 2020 from 45.2 as of Dec 31, 2019.
Shareholders’ equity as of Jun 30, 2020 was $47.4 billion, up 8.1% year over year.
Share Buyback
Year to date through Jul 29, 2020, the company repurchased 8.3 million shares of common stock for $1.5 billion.
2020 Guidance
The company’s earlier-issued guidance for the full year was intact, indicating earnings per share to remain in the range of $18-$18.6 while adjusted revenues in the $154-$156 billion band.
Among other insurers that have released results so far, earnings of both UnitedHealth Group Inc. (UNH - Free Report) and Anthem Inc. surpassed the Zacks Consensus Estimate by 1.94% and 4.9%, respectively, while Centene Corp.’s (CNC - Free Report) bottom line missed estimates by 0.41%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Cigna (CI) Earnings Surpass Estimates in Q2, Improve Y/Y
Cigna Corp.’s (CI - Free Report) second-quarter 2020 earnings of $5.81 per share surpassed the Zacks Consensus Estimate by 15% and also grew 35% year over year.
Results reflected revenue and earnings growth owing to a strong fundamental performance and lower medical costs from deferred care following the COVID-19 pandemic.
Cigna’s revenues of $39.3 billion beat the Zacks Consensus Estimate by 4.2% and also increased 13.9% year over year mirroring solid contributions from each of the company's ongoing businesses.
The company’s medical enrollment grew by 86,000 lives from the prior-year quarter to 17.083 million customers, attributable to membership gains in the Government and International markets.
Selling, general and administrative expense ratio was 8.4, improved 60 basis points year over year on significant growth in revenues and cost-control measures.
Cigna Corporation Price, Consensus and EPS Surprise
Cigna Corporation price-consensus-eps-surprise-chart | Cigna Corporation Quote
Strong Segmental Performances
Health Services: Adjusted revenues of $28.6 billion were up 21.5% year over year, driven by insourcing of Integrated Medical pharmacy volumes and a sturdy performance in specialty pharmacy services, partly offset by a decline in retail script volumes.
Operating income of $1.25 billion increased 7% year over year, representing customer growth, higher adjusted pharmacy scripts volumes, benefits from effective management of the supply chain and a steady performance in specialty pharmacy services, partially offset by an increase in operating expenses to support growth
Integrated Medical: Adjusted revenues of $9.23 billion were up 3% year over year, highlighting customer wins in Medicare Advantage and in the Select segment, as well as premium growth. However, this upside was partially offset by premium relief programs for clients that were carried out in response to the COVID-19 pandemic.
Operating income of $1.52 billion surged 53.83% year over year on significantly lower medical utilization in both the Commercial and Government segments compared with the historic patterns. However, this uptrend was partially offset by premium relief programs for clients and cost share waivers for customers.
International Markets: Adjusted revenues of $1.43 billion were up 3.1% year over year, reflecting consistent business growth, partially offset by an adverse foreign currency movement.
Operating earnings of $319 million soared 54.1% year over year, driven by lower claim levels amid the COVID-19 pandemic, constant business gains and operational efficiency.
Group Disability and Other Operations
Adjusted revenues of $1.33 billion inched up 1.5% year over year. Operating earnings of $132 million were down 11.4% year over year due to elevated claims in Cigna’s Life business, primarily related to the COVID-19 pandemic. However, this downside was partially mitigated by a favorable performance within the Disability business.
Capital Position
Cigna’s debt-to-capitalization ratio improved to 43.5 as of Jun 30, 2020 from 45.2 as of Dec 31, 2019.
Shareholders’ equity as of Jun 30, 2020 was $47.4 billion, up 8.1% year over year.
Share Buyback
Year to date through Jul 29, 2020, the company repurchased 8.3 million shares of common stock for $1.5 billion.
2020 Guidance
The company’s earlier-issued guidance for the full year was intact, indicating earnings per share to remain in the range of $18-$18.6 while adjusted revenues in the $154-$156 billion band.
Zacks Rank and Other Releases
Cigna carries a Zacks Rank #2 (Buy), currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Among other insurers that have released results so far, earnings of both UnitedHealth Group Inc. (UNH - Free Report) and Anthem Inc. surpassed the Zacks Consensus Estimate by 1.94% and 4.9%, respectively, while Centene Corp.’s (CNC - Free Report) bottom line missed estimates by 0.41%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>